A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib
Latest Information Update: 20 Aug 2022
At a glance
- Drugs Regorafenib (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms RESORCE
- Sponsors Bayer; Bayer HealthCare
- 02 Jul 2022 Results of a network analysis of data pooled from 3 global (ReDOS, CORRECT, RECOURSE) and 3 Asian (TERRA, Yoshino 2012, and CONCUR) studies assessed the impact of regorafenib dose optimization on clinical outcomes compared to best supportive care and TAS-102 in the treatment of relapsed/refractory metastatic colorectal cancer presented at the 24th World Congress on Gastrointestinal Cancer
- 08 Jun 2021 Results assessing anchored matching-adjusted indirect comparison between regorafenib and cabozantinib from two studies (CELESTIAL and RESORCE) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 19 May 2020 According to an Ipsen media release, preliminary data from the MAIC were presented by Dr. Katie Kelley at the 13th Annual Conference of the International Liver Cancer Association (ILCA 2019) in September 2019.